Hostname: page-component-745bb68f8f-hvd4g Total loading time: 0 Render date: 2025-01-16T16:58:42.932Z Has data issue: false hasContentIssue false
  • English
  • Français

Minimizing Antimicrobial Resistance in Hospital Bacteria: Can Switching or Cycling Drugs Help?

Published online by Cambridge University Press:  02 January 2015

John E. McGowan Jr.
John E. McGowan Jr.*
Affiliation:
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, and the Clinical Microbiology Laboratory, Grady Memorial Hospital, Atlanta, Georgia
*
Director, Clinical Microbiology (Box 248), Grady Memorial Hospital, 80 Butler Street, Atlanta, GA 30335
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Infection Control & Hospital Epidemiology , Volume 7 , Issue 12 , December 1986 , pp. 573 - 576
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1986

References

1. McGowan, JE Jr: Changing etiology of nosocomial bacteremia and fungemia and other hospital-acquired infections. Rev Infect Dis 1985; 7(Suppl 3):S357-S370.Google Scholar
2. McGowan, JE Jr: Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983; 5:1033–1048.CrossRefGoogle ScholarPubMed
3. McGowan, JE Jr: Is antimicrobial resistance in hospital microorganisms related to antibiotic use? Bull NY Acad Med {in press).Google Scholar
4. Levin, S, Karakusis, PH: Future trends in aminoglycoside therapy. Am J Med 1986; 80(Suppl 6B):190–194.Google Scholar
5. Berk, SL, Alvarez, S, Ortega, G, et al: Clinical and microbiologic consequences of amikacin use during a 42-month period. Arch Intern Med 1986; 146:538–541.Google Scholar
6. Yurasek, MC, Wang, WL, Mostow, SR: Reduction in gentamicin resistance among gram-negative bacilli with the exclusive use of amikacin. Clin Res 1981; 29:92A (abstract).Google Scholar
7. Moody, MM, deJongh, CA, Schimpff, SC, et al: Long term amikacin use: Effects on aminoglycoside susceptibility patterns of gram-negative bacilli. JAMA 1982; 248:1199–1202.Google Scholar
8. Wielunsky, E, Drucker, M, Cohen, T, et al: Replacement of gentamicin by amikacin as a means of decreasing gentamicin resistance of gram-negative rods in a neonatal intensive care unit. Isr J Med Sci 1983; 19:1006–1008.Google Scholar
9. Cross, AS, Opal, S, Kopecko, DJ: Progressive increase in antibiotic resistance of gram-negative bacterial isolates: Walter Reed Hospital, 1976 to 1980: Specific analysis of gentamicin, tobramycin, and amikacin resistance. Arch Intern Med 1983; 143:2075–2080.CrossRefGoogle ScholarPubMed
10. Betts, RF, Valenti, WM, Chapman, SW, et al: Five-year surveillance of aminogly-coside usage in a university hospital. Ann Intern Med 1984; 100:219–222.CrossRefGoogle ScholarPubMed
11. Saravolatz, LD, Arking, L, Pohlod, D, et al: An outbreak of gentamicin-resistant Klebsiella pneumoniae: Analysis of control measures. Infect Control 1984; 5:79–84.CrossRefGoogle ScholarPubMed
12. Shulman, ST, Yogev, R: Treatment of pediatric infections with amikacin as firstline aminoglycoside. Am J Med 1985; 79(Suppl 1A):43–50.Google Scholar
13. Levine, JF, Maslow, MJ, Leibowitz, RE, et al: Amikacin-resistant gram-negative bacilli: Correlation of occurrence with amikacin use. J Infect Dis 1985; 151:295–300.Google Scholar
14. Gerding, DN, Larson, TA: Aminoglycoside resistance in gram-negative.bacilli during increased amikacin use. Am J Med 1985; 79(Suppl 1A):l–7.Google ScholarPubMed
15. Young, EJ, Sewell, CM, Koza, MA, et al: Antibiotic resistance patterns during aminoglycoside restriction. Am J Med Sci 1985; 290:223–227.Google Scholar
16. Acar, JF, Goldstein, FW, Menard, R, et al: Strategies in aminoglycoside use and impact on resistance. Am J Med 1986; 80(Suppl 6B):82–87.Google Scholar
17. Saavedra, S, Vera, D, Ramirez-Ronda, CH: Susceptibility of aerobic gram-negative bacilli to aminoglycosides—Effects of 45 months of amikacin as first-line aminoglycoside therapy. Am J Med 1986; 80(Suppl 6B):65–70.Google Scholar
18. Ruiz-Palacios, GM, Ponce de Leon, S, Sifuentes, J, et al: Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin. Am J Med 1986; 80(Suppl 6B):71–75.CrossRefGoogle ScholarPubMed
19. Van Landuyt, HW, Boelaert, J, Glibert, B, et al: Surveillance of aminoglycoside resistance—European data. Am J Med 1986; 80(Suppl 6B):76-81.Google Scholar
20. Gerding, DN, Larson, TA: Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985. Am J Med 1986; 80(Suppl 6B):22–28.CrossRefGoogle ScholarPubMed
21. Young, LS, Hindler, J: Aminoglycoside resistance: A worldwide perspective. Am J Med 1986; 80(Suppl 6B):15–21.Google Scholar
22. Mayer, KH: Review of epidemic aminoglycoside resistance worldwide. Am J Med 1986; 80(Suppl 6B):56–64.Google Scholar
23. Bryan, CS, Parker, E, Schoenlein, PV, et al: Plasmid-mediated antibiotic resistance in a changing hospital environment: Efficacy of control measures. Am J Infect Control 1980; 8:65–71.Google Scholar
24. John, JF Jr, Rubens, CE, Farrar, WE Jr: Characteristics of gentamicin resistance in nosocomial infections. Am J Med Sci 1980; 279:25–30.Google Scholar
25. Weinstein, RA, Nathan, C, Gruensfelder, R, et al: Endemic aminoglycoside resistance in gram-negative bacilli: Epidemiology and mechanism. J Infect Dis 1980; 141:338–345.CrossRefGoogle Scholar
26. Lane, MM, Parker, DE, Flournoy, DJ: Trends in bacterial susceptibility to antimicrobial agents. Chemotherapy 1985; 31:433–439.CrossRefGoogle ScholarPubMed
27. Mickelsen, PA, Plorde, JJ, Gordon, KP, et al: Instability of antibiotic resistance in a strain of Staphylococcus epidermidis isolated from an outbreak of prosthetic valve endocarditis. J Infect Dis 1985; 152:50–58.Google Scholar
28. Cherubin, CE, Eng, RHK, Dabernat, H, Lareng, MB: Comparison of antibiotic resistance of gram-negative bacilli with beta-lactam and aminoglycoside antibiotics. Diagn Microbiol Infect Dis 1986; 4:153–159.CrossRefGoogle ScholarPubMed
29. Daschner, F, et al: Antibiotic resistance in intensive care unit areas. Infect Control 1983; 4:382–387.CrossRefGoogle ScholarPubMed
30. Shimizu, K, Kumada, T, Hsieh, W, et al: Comparison of aminoglycoside resistance patterns in Japan, Formosa, and Korea, Chile, and the United States. Antimicrob Agents Chemother 1985; 28:282–288.CrossRefGoogle ScholarPubMed
31. Goossens, H, Van Laethem, Y, Levy, J, et al: Predicting gentamicin resistance from annual usage in hospital. Lancet 1986; 2:804–805.Google Scholar
32. Magnussen, CR, Jacobson, MT: Longitudinal analysis of endemic gentamicin and tobramycin-resistant gram-negative bacilli in a community hospital. Infect Control 1984; 5:88–92.Google Scholar
33. Van Nhieu, GT, Goldstein, FW, Pinto, ME, et al: Transfer of amikacin resistance by closely related plasmids in members of the family Enterobacteriaceae isolated in Chile. Antimicrob Agents Chemother 1986; 29:833–837.Google Scholar
34. Tolmasky, ME, Roberts, M, Woloj, M, et al: Molecular cloning of amikacin resistance determinants from a Klebsiella pneumoniae plasmid. Antimicrob Agents Chemother 1986; 30:315–320.Google Scholar
35. Phillips, I, King, A, Shannon, K: Prevalence and mechanisms of aminoglycoside resistance. A ten-year study. Am J Med 1986; 80(Suppl 6B):48–55.CrossRefGoogle ScholarPubMed
36. Lee, SC, Gerding, DN, Cleary, PP: Hospital distribution, persistence, and reintroduction of related gentamicin R plasmids. Antimicrob Agents Chemother 1986; 29:654–659.Google Scholar
37. Larson, TA, Garrett, CR, Gerding, DN: Frequency of aminoglycoside 6'-Nacetyltransferase among Serratia species during increased use of amikacin in the hospital. Antimicrob Agents Chemother 1986; 30:176–178.CrossRefGoogle ScholarPubMed
38. Isenberg, HD, Berkman, JI: The role of drug-resistant and drug-selected bacteria in nosocomial disease. Ann NY Acad Sci 1971; 182:52–58.Google Scholar
39. Gardner, DA, Lorian, V: Bacterial susceptibility to antibiotics remains virtually stable. Antimicrobic Newsletter 1985; 2:9–13.Google Scholar
40. Manu, P: Empiric use of aminoglycosides in hospitals. Ann Intern Med 1984; 100:919.Google Scholar
41. Sanders, CC, Sanders, WE Jr: Microbial resistance to newer generation betalactam antibiotics: Clinical and laboratory implications. J Infect Dis 1985; 151:399–406.CrossRefGoogle ScholarPubMed
42. Woloj, M, Tolmasky, ME, Roberts, MC, et al: Plasmid-encoded amikacin resistance in multiresistant strains of Klebsiella pneumoniae isolated from neonates with meningitis. Antimicrob Agents Chemother 1986; 29:315–319.Google Scholar
43. Neu, HC: Antimicrobial activity, bacterial resistance, and antimicrobial pharmacology: Is it possible to use new agents cost-effectively? Am J Med 1985; 78(Suppl6B):17–22.CrossRefGoogle ScholarPubMed
44. Aldis, WL, Cowan, D: Cost-effectiveness of antibiotic use. JAMA 1984; 252:3252.Google Scholar
45. Jorgensen, JH: Susceptibility test methods which may be able to predict the emergence of resistance to newer beta-lactam antibiotics. Chemioterapia 1985; 4:7–13.Google Scholar
46. Quintiliani, R, Klimek, JJ, Nightingale, CH: Restriction policies for therapy with combination antibiotics. J Infect Dis 1986; 153:645–647.Google Scholar
47. Schaberg, DR, Power, G, Betzold, J, et al: Conjugative R plasmids in antimicrobial resistance of Staphylococcus aureus causing nosocomial infections. J Infect Dis 1985; 152:43–49.Google Scholar